Comparative Pharmacology
Head-to-head clinical analysis: CLINORIL versus KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINORIL versus KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE.
CLINORIL vs KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, and antipyretic effects. Sulindac is a prodrug converted to the active sulfide metabolite.
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Phenylephrine is a selective alpha-1 adrenergic receptor agonist, causing vasoconstriction.
150-200 mg orally twice daily, with maximum daily dose of 400 mg.
Ophthalmic: 1 drop of the combination (ketorolac tromethamine 0.45% and phenylephrine hydrochloride 1%) into the operative eye three times daily, beginning 1 day prior to surgery and continuing on the day of surgery and for 2 weeks postoperatively.
None Documented
None Documented
7.8 hours (terminal); clinical context: prolonged in elderly and renal impairment, requiring dose adjustment.
Ketorolac: 2.4-8.6 hours (mean 5.3 hours) in young adults; prolonged in elderly (up to 13.9 hours) and renal impairment. Phenylephrine: 2-3 hours.
Renal: 50% as unchanged drug, 25% as glucuronide conjugate; Biliary/Fecal: 25% as metabolites.
Ketorolac: ~92% renal (60% as unchanged drug, 32% as metabolites), 6% fecal. Phenylephrine: primarily renal as metabolites (sulfate conjugates) with <1% unchanged.
Category C
Category D/X
NSAID
NSAID